187 related articles for article (PubMed ID: 37480430)
21. Development and validation of a metabolic gene signature for predicting overall survival in patients with colon cancer.
Ren J; Feng J; Song W; Wang C; Ge Y; Fu T
Clin Exp Med; 2020 Nov; 20(4):535-544. PubMed ID: 32772211
[TBL] [Abstract][Full Text] [Related]
22. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
[TBL] [Abstract][Full Text] [Related]
23. A Metabolism-Related Gene Prognostic Index for Prediction of Response to Immunotherapy in Lung Adenocarcinoma.
Tang B; Hu L; Jiang T; Li Y; Xu H; Zhou H; Lan M; Xu K; Yin J; Su C; Zhou C; Xu C
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293001
[TBL] [Abstract][Full Text] [Related]
24. A novel chromatin regulator signature predicts the prognosis, clinical features and immunotherapy of colon cancer.
Li X; Huo X; Zhao C; Chen Z; Xu Z; Yu J; Sun X
Epigenomics; 2022 Nov; 14(21):1325-1341. PubMed ID: 36545887
[No Abstract] [Full Text] [Related]
25. Identification of an Immune Signature Predicting Prognosis Risk and Lymphocyte Infiltration in Colon Cancer.
Li X; Wen D; Li X; Yao C; Chong W; Chen H
Front Immunol; 2020; 11():1678. PubMed ID: 33013820
[TBL] [Abstract][Full Text] [Related]
26. Identification of a novel cellular senescence-related signature for the prediction of prognosis and immunotherapy response in colon cancer.
Dai L; Wang X; Bai T; Liu J; Chen B; Li T; Yang W
Front Genet; 2022; 13():961554. PubMed ID: 35991564
[TBL] [Abstract][Full Text] [Related]
27. An Activated Dendritic-Cell-Related Gene Signature Indicative of Disease Prognosis and Chemotherapy and Immunotherapy Response in Colon Cancer Patients.
Ouyang Y; Yu M; Liu T; Suo M; Qiao J; Wang L; Li N
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958942
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy.
Bao X; Zhang H; Wu W; Cheng S; Dai X; Zhu X; Fu Q; Tong Z; Liu L; Zheng Y; Zhao P; Fang W; Liu F
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028695
[TBL] [Abstract][Full Text] [Related]
29. Constructing and validating a risk model based on neutrophil-related genes for evaluating prognosis and guiding immunotherapy in colon cancer.
Wang S; Wang L; Qiu M; Lin Z; Qi W; Lv J; Wang Y; Lu Y; Li X; Chen W; Qiu W
J Gene Med; 2024 Apr; 26(4):e3684. PubMed ID: 38618694
[TBL] [Abstract][Full Text] [Related]
30. A novel enterocyte-related 4-gene signature for predicting prognosis in colon adenocarcinoma.
Cheng X; Wei Y; Fu Y; Li J; Han L
Front Immunol; 2022; 13():1052182. PubMed ID: 36532007
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
32. A novel m6A/m5C/m1A score signature to evaluate prognosis and its immunotherapy value in colon cancer patients.
Liu J; Dou M; Liu X; Lu Y; Lu W
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11995-12012. PubMed ID: 37421455
[TBL] [Abstract][Full Text] [Related]
33. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
Front Immunol; 2022; 13():967277. PubMed ID: 36466837
[TBL] [Abstract][Full Text] [Related]
34. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
[TBL] [Abstract][Full Text] [Related]
35. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
Yang X; Tang W; He Y; An H; Wang J
Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
[TBL] [Abstract][Full Text] [Related]
36. Construction and validation of a prognostic model for colon adenocarcinoma based on bile acid metabolism-related genes.
Luo Q; Zhou P; Chang S; Huang Z; Zeng X
Sci Rep; 2023 Aug; 13(1):12728. PubMed ID: 37543674
[TBL] [Abstract][Full Text] [Related]
37. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
38. Identification of Molecular Subtypes and a Prognostic Signature Based on Inflammation-Related Genes in Colon Adenocarcinoma.
Qiu C; Shi W; Wu H; Zou S; Li J; Wang D; Liu G; Song Z; Xu X; Hu J; Geng H
Front Immunol; 2021; 12():769685. PubMed ID: 35003085
[TBL] [Abstract][Full Text] [Related]
39. Fatty Acid Metabolism Signature Contributes to the Molecular Diagnosis of a Malignant Gastric Cancer Subtype with Poor Prognosis and Lower Mutation Burden.
Chen Z; Cheng G
Recent Pat Anticancer Drug Discov; 2023 Sep; ():. PubMed ID: 37691229
[TBL] [Abstract][Full Text] [Related]
40. Prognostic costimulatory molecule-related signature risk model correlates with immunotherapy response in colon cancer.
Huang W; Su D; Liao X; Yang T; Lu Y; Zhang Z
Sci Rep; 2023 Jan; 13(1):789. PubMed ID: 36646765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
